This webinar discusses the FDA's accelerated approval of venetoclax for the treatment of people with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, including those with 17p deletion. Venetoclax is a small molecule inhibitor of the BCL-2 protein and was granted Breakthrough Therapy Designation by the FDA in April 2015 for the treatment of people with previously treated (relapsed or refractory) CLL with 17p deletion.
Grzegorz S. Nowakowski, MO, Division of Hematology, Mayo Clinic, Rochester, MN
Lori Ehrlich, MD, Division of Hematology Products, Office of Hematology and Oncology Products, U.S. Food and Drug Administration, Silver Spring, MD
Richard R. Furman, MD, Department of Hematology/Oncology, Weill Cornell Medical College, New York, NY